Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models

Anticancer Research

Volumn 28, Issue 5 A, 2008, Pages 2769-2774

  Tejeda, Miguel ^a   Gaal, D ^a   Hullan L ^a   Csuka, O ^a   Schwab, R ^b   Szokoloczi, O ^b   Keri G Y ^b  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Implanted pump; Rodent and human tumor models; Somatostatin analog; TT 232

Indexed keywords

DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLCYSTEINYLTHREONINAMIDE 2,6 DISULFIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; COLON ADENOCARCINOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; MELANOMA; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; SARCOMA; SQUAMOUS CELL CARCINOMA;

ANIMALS; HUMANS; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, SUBCUTANEOUS; MICE; NEOPLASMS, EXPERIMENTAL; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 55749109383     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Schally AV, Coy DH and Meyers CA: Hypothalamic regulatory hormones. Annu Rev Biochem 47: 89-128, 1978 .
2. Brazeau P, Vale W and Surges R: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77-79, 1973.
3. Reichlin S: Somatostatin. N Engl J Med 309: 1495-1501, 1983.
4. Robbins RJ: Somatostatin and cancer. Metabolism 45: 95-100, 1996.
5. Evers BM, Parekh D, Townsend CM and Thompson JC: Somatostatin and analogues in the treatment of cancer. Ann Surg 213(3): 190-198, 1991.
6. Kéri Gy, Mezo I, Vadász Zs, Horváth A, Idei M, Vantus T, Balogh A, Bököny G, Bajor T, Teplán I, Tamás J, Mak M, Horváth J and Csuka O: Structure activity relationship studies of novel Somatostatin analogs with antitumor activity. Peptide Res 6: 281-288, 1993.
7. Kéri Gy, Mezo I, Vadász Zs, Horváth A, Idei M, Vantus T, Balogh A, Bököny G, Bajor T, Teplán I, Tamás J and Horváth J: Novel Somatostatin analogs with antitumor activity. Peptide Chem 48: 334-336, 1992.
8. Kéri Gy, Érchegyi J, Horváth A, Mezo I, Idei M, Vantus T, Balogh A, Vadász Zs, Bököny G, Teplán I, Csuka O, Tejeda M, Gaál D, Szegedi Z, Szende B, Roze C, Kalthoff H and Ullrich A: A tumor-selective Somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci USA 93(22): 12513-12518, 1996.
9. Kéri Gy, Mezo I, Horvath A, Vadász Zs, Balogh Á, Idei M, Vantus T, Teplán I, Mák J, Horváth J, Pál K and Csuka O: Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity. Biochem Bio Res Comm 191: 681-687, 1983.
10. Vántus T, Kéri Gy, Kriviczkine Z, Valius M, Steták K, Keppens S, Csermely P, Bauer P, Kököny G, Declercq W, Vandenabeele P, Merlevede W and Vandenheede JR: The somatostatin analogue TT-232 induces apoptosis in A-431 cells: sustained activation of stress-activated kinases and inhibition of signaling to extracellular signal-regulated kinases. Cell Signal 13(10): 717-723, 2001.
11. Szende B, Zalatnai A and Schally AV: Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogues of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 86: 1643-1647, 1989.
12. Fischer DE: Apoptosis in cancer therapy. Cell 78: 539-542, 1994.
13. Diaconu CC, Szatmari M, Kéri Gy and Venetianer A: Apoptosis in induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue, TT-232. Br J Cancer 80: 1197-1203, 1999.
14. Colas B, Cambillau C, Buscail L, Zeggari M, Esteve JP, Lautre V, Thomas F, Vaysse N and Sussini C: Stimulation of a membrane tyrosine phosphatase activity of somatostatin analogues in rat pancreatic acinar cells. Eur J Biochem 207: 1017-1022, 1992.
15. Levitt ML and Kotty PP: Tyrosine kinase inhibition in preclinical development. Invest New Drugs 17: 213-226, 2002.
16. Dasgupta P: Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia and angiogenesis. Pharmacol Therap 102(1): 61-65, 2004.
17. Helyes Z, Pinter E and Szolcsanyi J: TT-232-somatostatin ss(1)/ss(4) receptor agonist treatment of neuropathic pain treatment in inflammation. Drugs Future 31(6): 558-566, 2005.
18. Engstrom M, Savola JM and Wurster S: Differential efficacies of somatostatin receptor agonists for G-protein activation and desensitization of somatostatin receptor subtype 4-mediated responses. J Pharmacol Exp Therap 316(3): 1262-1268, 2006.
19. Crider AM and Witt KA: Somatostatin sst (4) ligands: chemistry and pharmacology. Med Chem 7(3): 213-220, 2007.
20. Simon A, Keri Gy and Kardos J: Comparison of the binding modes of TT-232 in somatostatin receptors type 1 and 4. J Mol Struc-Theo Chem 816(1-3): 73-76, 2007.
21. Schally AV: Oncological application of somatostatin analogue. Cancer Res 48: 1566-1570, 1988.
22. Stetak A, Lankenau A, Vantus T, Csermely P, Ullrich A and Kéri Gy: The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src. Biochem Biophys Res Commun 285: 483-488, 2001.
23. Guide for the Care and Use of Laboratory Animals. US Dept. of Health and Human Services NIH Publication, No 85-23 Washington, USA, 1985.
24. Clark JD, Baldwin RL, Bayne KA, Brown MJ, Gethart GF, Gonder JC, Gwattmey JK, Keeling ME, Kohn DF, Robb JW, Smith OA, Steggerda JA, Vandenbergh JG, White WJ, Williams-Blangero S and Vanderbergh JL: Guide for the Care and Use of Laboratory Animals. Washington DC, USA: National Academy Press, 1996.
25. Szokoloczi O, Schwab R, Peták I, Örfi L, Pap A, Eberle A, Szuts T and Kéri Gy: TT-232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases. J Recep Sig Transd 25: 217-235, 2005.
26. Kéri Gy, Schwab R, Szokoloczi O, Szuts T and Szolcsányi J: TT-232: in anti-tumour and anti-inflammatory peptide therapeutic in clinical development. Int J Pep Res Ther 11(1): 3-15, 2005.
27. Alza Corporation, Alza Technical Information Manual, Vol. 2: pp. 2-28 CA, USA, 1994.
28. Fara JM: Osmotic delivery systems for research. Methods Enzymol 112: 470-784, 1995.
29. Györffy E, Horváth A and Mezo I: Investigation of the chemical stability of TT-232 and its analogues HPLC. J Peptide Sci 4: 45-46, 1998.
30. Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Can Chem Pharm 24: 18, 1995.
31. Inoue K, Onishi H, Kato Y, Michiura T, Nakai K, Sato M, Yamamichi K, Machida Y and Nakane Y: Comparison of intraperitoneal continuous infusion of floxuridine and bolus administration in a peritoneal gastric cancer xenograft model. Cancer Chemther Pharmacol 53(5): 415-422, 2004.
32. Kuroiwa M, Takeuchi T, Lee JH, Yoshizawa J, Hirato J, Kaneko S, Choi SH, Suzuki N, Ikeda H and Tsuchida Y: Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. J Pediatr Surg 38(10): 1499-1505, 2003.
33. Djalilian HR, Caicedo E, Lessan K, Grami V, Le CT, Spellman SR, Pambuccian S, Hall WT, Low WA and Ondrey FG: Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats. Cancer Immunol Immunther 56(8): 1207-1214, 2007.
34. Drixler T, Borel Rinkes I, Ritchie E, van Vroonhover T, Gebbink M and Voert E: Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metatases after partial hepatectomy. Cancer Res 60: 1761-1765, 2000.
35. Kisker O, Backer Ch, Prox D, Fannom M, D'Amato R, Flynn A, Fogler W, Lee Sim B, Allred E, Steven A, Piric-Shepherd E and Folkman J: Continuous administration of endostatin by intraperitonealy osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61: 7669-7674, 2001.